Council on Peripheral Vascular Disease (PVD)
Message from the Chair@Model.Item.RenderHeadingSizeTag("h2")>
The Council on Peripheral Vascular Disease (PVD) seeks to integrate the academic and clinical missions of all interdisciplinary vascular health professionals in order to expand professional and public vascular education; to advance the basic science and clinical research and evidence based practice; and to thereby improve clinical outcomes of individuals with PVD.
Naomi Hamburg, MD, MS, FAHA
Chair, Peripheral Vascular Disease Council
The PAD Awareness Task Force’s mission is “working to improve the detection of symptomatic PAD by patients and providers to facilitate guideline-based treatment which will improve cardiovascular outcomes, walking fitness, and quality of life.
PVD Council Chair, Aruna D. Pradhan, MD, MPH, speaking during Vascular Discovery 2018The PVD Council is currently collaborating with ISTH and the American Venous Forum on a white paper on research priorities in VTE.
PVD Award from Vascular Discovery 2018The PVD Council funds several awards that support student, early career, and mid-career members recognized at Scientific Sessions and Vascular Discovery conferences.
The PVD Early Career (EC) Committee is a vibrant and dynamic group within the PVD Council. The EC works closely with PVD Leadership and Membership committees to recruit and promote early career vascular specialists from clinical, research, and education backgrounds. In addition, the EC helps organize PVD Council's fellows in training curriculum which occurs on Saturday of Scientific Sessions annually. This curriculum serves as a platform for year-in-review presentations on critical issues in the care of vascular patients as well as a forum for young AHA members entering into the care of vascular patients.
Geoffrey Barnes, MD, MSc, FAHAGeoffrey Barnes, MD, MSc, FAHA
Dr. Barnes is a cardiologist and vascular medicine specialist at the University of Michigan. His clinical practice and research interest is in the management of patients with venous thromboembolism, peripheral artery disease, or taking anticoagulants. He has funding from the National Heart, Lung, and Blood institute to improve the safe delivery of peri-procedural anticoagulants as well as serving as co-director of the Michigan Anticoagulation Quality Improvement Initiative (MAQI2).
PVD Fellow, McDermott Named Distinguished Scientist
Mary M. McDermott, MD, FAHA
Dr. McDermott is a leading clinician investigator studying lower extremity peripheral artery disease (PAD). Traditionally, the natural history of lower extremity outcomes in people with PAD and intermittent claudication was considered ‘benign’, because most people with PAD do not develop critical limb ischemia or worsening leg symptoms. Using a prospective study design with systematic assessment of objectively measured walking performance over time, Dr. McDermott’s investigative team demonstrated that people with PAD have greater functional impairment and faster functional decline than people without PAD.
Want to get involved? @Model.Item.RenderHeadingSizeTag("h2")>
The American Heart Association depends on the time and talent of volunteers to help us create a healthier world, free of heart disease and stroke.
Vascular Discovery: From Genes to Medicine @Model.Item.RenderHeadingSizeTag("h2")>
This annual meeting includes diverse disciplines within the arteriosclerosis, thrombosis, vascular biology, peripheral vascular disease, vascular surgery, and functional genomics research communities.
CME Education - Peripheral Artery Disease Simulation Series @Model.Item.RenderHeadingSizeTag("h2")>
Test your clinical assessment and critical thinking skills as you evaluate and manage patients with peripheral artery disease (PAD).
Funding Opportunities @Model.Item.RenderHeadingSizeTag("h2")>
The method for applying for funding is Web-based, using our electronic system, ProposalCentral.
PVD Council Awards @Model.Item.RenderHeadingSizeTag("h2")>
The PVD Council proudly sponsors award programs that honor the efforts of its members and their outstanding research.